Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma

Huskey, Janna L., MD1; Heilman, Raymond L., MD1; Khamash, Hasan, MD1; Fonseca, Rafael, MD1

doi: 10.1097/TP.0000000000002449
Reviews

Chronic kidney disease is common in patients with multiple myeloma. Historically, individuals with end-stage renal disease and multiple myeloma did poorly with renal transplantation due to higher mortality rates from the malignancy itself or associated comorbidities. However, over the past 2 decades, there have been significant advances in the treatment of multiple myeloma with the advent of new therapeutic agents resulting in an improvement of long-term survival. As a result, more individuals with multiple myeloma are being referred for kidney transplantation, especially those with good functional capacity and minimal comorbidities. Recent literature has suggested that certain patients with multiple myeloma can successfully undergo renal transplantation after stem transplantation with consideration for maintenance therapy, although caution should be used with immunomodulating drugs due to the anecdotally reported risk of acute rejection. Therefore, having a multidisciplinary approach with the transplant team and hematology both before and after transplant is crucial in maximizing the chance of success for these individuals. This review summarizes the literature on renal transplantation in patients with multiple myeloma as well as the therapeutic advancements that have occurred which may allow certain patients to undergo successful transplantation.

The authors present data in order to safely and successfully transplant patients with a multiple myeloma through a close multidisciplinary approach between hematologists and transplant teams.

1 Department of Medicine, Mayo Clinic, Phoenix, AZ.

Received 25 May 2018. Revision received 22 August 2018.

Accepted 6 September 2018.

The authors declare no funding or conflicts of interest.

Rafael Fonseca Consulting: Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, AbbVie. Scientific Advisory Board Adaptive Biotechnologies. Mayo Clinic and Rafael, Fonseca hold a patent for the prognostication of myeloma using FISH.

J.L.H. participated in the writing of this article. R.L.H. participated in the writing of this article, H.K. participated in the writing of this article. R.F. participated in the writing of this article.

Correspondence: Raymond L. Heilman, MD, 5777 East Mayo Boulevard, Phoenix, AZ 85054. (Heilman.Raymond@mayo.edu).

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.